低剂量抗PD (L) 1用于治疗固体恶性瘤
Iza Andrade de A Souza1, Beatriz de M Dobbert1, Barbara G Sao Jose1
1Division of Medical Oncology, Hospital de Base-FUNFARME, São José do Rio Preto, Brazil.
JCO global oncology
|November 21, 2024
概括
较低剂量的抗PD(L) 1癌症疗法与传统剂量具有相似的疗效,提供了潜在的更容易获得的治疗选择. 需要进一步的随机试验来证实这些发现,以便更广泛的临床应用.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药物经济学 药物经济学
背景情况:
- 抗编程死亡 (联结体) 1 (抗PD(L) 1) 剂在癌症治疗中至关重要.
- 有证据表明,较低的剂量可以保持有效性,同时降低成本.
研究的目的:
- 在患有固体恶性瘤的患者中,比较低剂量 (LD) 与常规剂量 (CD) 抗PD (L) 1治疗的疗效和结果.
- 评估LD抗PD的潜力,作为一个具有成本效益的替代品.
主要方法:
- 在巴西Base医院进行的观察性研究,评估了用抗PD(L) 1药物 (LD或CD) 治疗固体瘤的患者.
- 患者根据初始循环剂量相对于标签批准的数量进行了分类.
- 衡量的疗效结果包括最佳整体应答率 (cORR),无临床进展生存率 (cPFS) 和整体生存率 (OS).
主要成果:
- 包括71名患者:49人 (69%) 接受了LD,22人 (31%) 接受了CD抗PD (L)
- 最常见的癌症是肺癌和皮肤癌 (黑色素瘤); pembrolizumab 是最常用的药物.
- 在cORR (38.1%对35.2%),cPFS (5.3对7个月) 或OS (12.8个月对未达到) 中没有观察到LD和CD组之间的显著差异.
- 对 pembrolizumab 接受者的子组分析产生了类似的非显著结果.
结论:
- 低剂量抗PD(L) 1疗法在响应率,无进展存活率和整体存活率方面表现出与常规剂量相当的疗效.
- LD抗PD (L) 1提供了一种潜在的替代方案,以提高治疗的可访问性.
- 建议通过随机对照试验进行进一步的调查,以验证这些发现.
更多相关视频
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.5K
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.5K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:24Parkinson's Disease: Treatment
220
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
220
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K